Mounjaro 2.5mg weight loss results: what actually happens at the starting dose

Why 2.5mg results look different from the trial headlines

The figures people most often quote from Mounjaro studies (around 20% average body-weight loss) come from participants who completed 72 weeks at the highest doses they could tolerate, not from their first four weeks at 2.5mg. It helps to hold that in mind if the scales haven't shifted much yet.

At 2.5mg, tirzepatide activates both GIP and GLP-1 receptors, slowing gastric emptying and reducing appetite, but at a low level. The dose is set where it is specifically because starting lower means fewer people stop treatment early due to nausea or vomiting. You can read more about how this first pen fits into the broader treatment journey on our Mounjaro 2.5mg weight loss page.

So what is realistic to see? Some people lose 1–3 kg during their first four weeks. Others lose less, a small number lose more, and a few find the scales barely move at all. All of those outcomes are normal at 2.5mg, and none of them tells you what will happen at 5mg, 7.5mg or beyond. The trajectory matters far more than the opening week.

It's worth being honest: if you're checking the scales every few days and feeling underwhelmed, that's understandable. Most people start this treatment having already tried a great deal. Patience at 2.5mg is not failure, it's the plan working as designed.

What the tirzepatide 2.5mg evidence actually shows

The SURMOUNT-1 trial, published in the New England Journal of Medicine, involved 2,539 adults with obesity and no diabetes. Participants were randomised to 5mg, 10mg or 15mg maintenance doses, meaning the trial data does not separate out a 2.5mg-only endpoint, because 2.5mg was always the starting point on the way to a maintenance dose.

What this means practically: tirzepatide 2.5mg weight loss results, taken in isolation, are not the subject of a standalone published figure. The evidence base is for the full titrated course. By 72 weeks, average weight loss at 15mg reached approximately 21% of starting body weight. At 10mg it was around 19%. These numbers reflect what tirzepatide can do when someone reaches and sustains a therapeutic maintenance dose, not what the starter pen delivers alone.

NICE's recommendation of tirzepatide (TA1026) is built on that full-course evidence. NICE notes that treatment should be reviewed if less than 5% weight loss is achieved after six months at the highest tolerated dose, which is a very different checkpoint from four weeks at 2.5mg. The comparison between 2.5mg and 5mg is covered in more detail on our 2.5mg vs 5mg weight loss page if you're weighing up what to expect at the next step.

The factors that shape your personal results at this stage

Several things affect how much you lose (or don't) in the first four weeks. Diet matters: tirzepatide reduces appetite, but the extent to which that translates into a calorie deficit depends partly on what you eat when hunger does ease. Protein and fibre support satiety; ultra-processed foods can blunt the effect. Physical activity, sleep quality and stress all interact with the hormones tirzepatide influences.

Side effects also play a role. If nausea is significant, some people eat less than they realise. Others find eating helps settle their stomach and unintentionally offset the deficit. Neither pattern is wrong, but it shapes the number on the scales. The full Mounjaro guide covers what to expect across the whole treatment arc.

Your starting weight matters too. People with a higher starting BMI often see larger absolute losses early on, though percentage loss tends to be the more useful comparison over time. Storage, injection technique and consistency of timing all have small but real effects. For detail on the pen format itself, the Mounjaro KwikPen guide is worth a read before your first injection.

One thing that doesn't shape your results: how quickly you progress to the next dose. Titration is a clinical decision, made by your prescriber based on tolerability and response, not a prize for early movers. Rushing to 5mg to 'get real results faster' is not how the medicine is designed to be used.

When to talk to your prescriber about your 2.5mg experience

After four weeks at 2.5mg, the standard pathway moves to 5mg, but that step is always clinically reviewed, not automatic. Your prescriber will want to know how you've tolerated the starter dose. If side effects were significant, staying at 2.5mg for another four weeks is a legitimate option; the licensed schedule allows for this. If you're buying Mounjaro through an online pharmacy, that review should happen before your next pen is dispensed. You can see how that process works at nume, sorry. You can see how that process works at how to buy Mounjaro online through a registered pharmacy.

It is also worth knowing which symptoms should prompt earlier contact. Severe or persistent stomach pain that radiates to the back needs urgent medical attention, the MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as an infrequent but serious risk with GLP-1 medicines. Signs of severe dehydration from prolonged vomiting or diarrhoea are another reason to seek help promptly rather than waiting for your scheduled review.

Results at 7.5mg and beyond tend to be more pronounced; our Mounjaro 7.5mg results page gives a sense of what the evidence shows at that stage. If you're at 5mg currently and wondering about the step after, the Mounjaro 5mg weight loss page covers the picture there. For a broader view of the treatment options available, our weight-loss treatments page is a good starting point, and speaking to our prescribers is the right next step if you want a clinical view on where you are in your own journey.